YSB Inc. (B1S.F)
- Previous Close
0.6850 - Open
0.6850 - Bid 0.6850 x --
- Ask 0.7350 x --
- Day's Range
0.6850 - 0.6850 - 52 Week Range
0.5900 - 0.9800 - Volume
58 - Avg. Volume
1 - Market Cap (intraday)
487.667M - Beta (5Y Monthly) --
- PE Ratio (TTM)
68.50 - EPS (TTM)
0.0100 - Earnings Date --
- Forward Dividend & Yield 0.01 (1.39%)
- Ex-Dividend Date May 23, 2025
- 1y Target Est
--
YSB Inc. develops digital pharmaceutical platform for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. The company develops ClouDiagnos for diagnostic testing service; wePharmacy, a 24-hour access smart unmanned pharmaceutical booth that connects buyers and the end customers with pharmacist services; SaaS solutions; and YSB eLearn that provides online courses for the preparation of the pharmacist qualification examinations. It also engages in the wholesale and retail of pharmaceutical and healthcare products. In addition, the company provides medical testing services. YSB Inc. was founded in 2015 and is headquartered in Guangzhou, China.
www.ysbang.cn6,763
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: B1S.F
View MorePerformance Overview: B1S.F
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: B1S.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: B1S.F
View MoreValuation Measures
Market Cap
487.67M
Enterprise Value
275.29M
Trailing P/E
113.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.21
Price/Book (mrq)
1.66
Enterprise Value/Revenue
0.13
Enterprise Value/EBITDA
88.40
Financial Highlights
Profitability and Income Statement
Profit Margin
0.17%
Return on Assets (ttm)
-1.02%
Return on Equity (ttm)
0.73%
Revenue (ttm)
17.9B
Net Income Avi to Common (ttm)
30.01M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.99B
Total Debt/Equity (mrq)
10.29%
Levered Free Cash Flow (ttm)
--